Advances on the molecular mechanism of metformin's antitumor effect

doi:10.12092/j.issn.1009-2501.2019.03.019

Abstract

Abstract:

Metformin is a classical drug with safety and efficacy for type 2 diabetes therapies, which are widely used in hypoglycemia. According to recent study, the morbidity and mortality of malignant tumors are lower in patients. Although the mechanism is unclear, metformin might become a potential antitumor drug. Research on the related pathways serves to reveal its mechanism, which is great significance for developing novel antitumor targets and drugs. This article reviews the molecular mechanisms of metformin on inhibition of tumors in AMPK dependent and non-dependent way.

Key words: metformin, tumor, AMPK, molecular mechanisms

CLC Number:

R966

DING Qiuhua, SHI Daohua. Advances on the molecular mechanism of metformin's antitumor effect[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 350-354.

References

［1］Shi Y, Hu FB. The global implications of diabetes and cancer［J］. Lancet, 2014, 383(9933): 1947-1948.
［2］Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients［J］. BMJ, 2005, 330(7503): 1304-1305.
［3］Noto H, Goto A, Tsujimoto T, et al. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis［J］. PLoS One, 2012, 7(3): e33411.
［4］Vancura A, Bu P, Bhagwat M, et al. Metformin as an Anticancer Agent［J］. Trends Pharmacol Sci, 2018, 39(10): 867-878.
［5］Umezawa S, Higurashi T, Nakajima A. AMPK: Therapeutic Target for Diabetes and Cancer Prevention［J］. Curr Pharm Des, 2017, 23(25): 3629-3644.
［6］Kurumbail RG, Calabrese MF. Structure and Regulation of AMPK［J］. EXS, 2016, 107: 3-22.
［7］Li W, Saud SM, Young MR, et al. Targeting AMPK for cancer prevention and treatment［J］. Oncotarget, 2015, 6(10): 7365-7378.
［8］Zakikhani M, Dowling R, Fantus IG, et al. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells［J］. Cancer Res, 2006, 66(21): 10269-10273.
［9］Hezel AF, Bardeesy N. LKB1; linking cell structure and tumor suppression［J］. Oncogene, 2008, 27(55): 6908-6919.
［10］Woods A, Johnstone SR, Dickerson K, et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade［J］. Curr Biol, 2003, 13(22): 2004-2008.
［11］Korsse SE, Peppelenbosch MP, van Veelen W. Targeting LKB1 signaling in cancer［J］. Biochim Biophys Acta, 2013, 1835(2): 194-210.
［12］Huang X, Wullschleger S, Shpiro N, et al. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice［J］. Biochem J, 2008, 412(2): 211-221.
［13］Li NS, Zou JR, Lin H, et al. LKB1/AMPK inhibits TGF-beta1 production and the TGF-beta signaling pathway in breast cancer cells［J］. Tumour Biol, 2016, 37(6): 8249-8258.
［14］Green AS, Chapuis N, Maciel TT, et al. The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation［J］. Blood, 2010, 116(20): 4262-4273.
［15］Hardie DG. The LKB1-AMPK pathway-friend or foe in cancer?［J］. Cancer Cell, 2013, 23(2): 131-132.
［16］Amin S, Lux A, O'Callaghan F. The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth［J］. Br J Clin Pharmacol, 2019, 85(1): 37-46.
［17］Dowling RJ, Zakikhani M, Fantus IG, et al. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells［J］. Cancer Res, 2007, 67(22): 10804-10812.
［18］Wang Y, Xu W, Yan Z, et al. Metformin induces autophagy and G0/G1 phase cell cycle arrest in myeloma by targeting the AMPK/mTORC1 and mTORC2 pathways［J］. J Exp Clin Cancer Res, 2018, 37(1): 63.
［19］Wandee J, Prawan A, Senggunprai L, et al. Metformin enhances cisplatin induced inhibition of cholangiocarcinoma cells via AMPK-mTOR pathway［J］. Life Sci, 2018, 207: 172-183.
［20］Zakikhani M, Blouin MJ, Piura E, et al. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells［J］. Breast Cancer Res Treat, 2010, 123(1): 271-279.
［21］Kamada R, Toguchi Y, Nomura T, et al. Tetramer formation of tumor suppressor protein p53: Structure, function, and applications［J］. Biopolymers, 2016, 106(4): 598-612.
［22］Sun Y, Tao C, Huang X, et al. Metformin induces apoptosis of human hepatocellular carcinoma HepG2 cells by activating an AMPK/p53/miR-23a/FOXA1 pathway［J］. Onco Targets Ther, 2016, 9: 2845-2853.
［23］Li P, Zhao M, Parris AB, et al. p53 is required for metformin-induced growth inhibition, senescence and apoptosis in breast cancer cells［J］. Biochem Biophys Res Commun, 2015, 464(4): 1267-1274.
［24］Gwak H, Kim Y, An H, et al. Metformin induces degradation of cyclin D1 via AMPK/GSK3beta axis in ovarian cancer［J］. Mol Carcinog, 2017, 56(2): 349-358.
［25］Wu D, Hu D, Chen H, et al. Glucose-regulated phosphorylation of TET2 by AMPK reveals a pathway linking diabetes to cancer［J］. Nature, 2018, 559(7715): 637-641.
［26］Cha JH, Yang WH, Xia W, et al. Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1［J］. Mol Cell, 2018, 71(4): 606-620.
［27］Kalender A, Selvaraj A, Kim SY, et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner［J］. Cell Metab, 2010, 11(5): 390-401.
［28］Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells［J］. Cell Cycle, 2009, 8(1): 88-96.
［29］Vigneri R, Goldfine ID, Frittitta L. Insulin, insulin receptors, and cancer［J］. J Endocrinol Invest, 2016, 39(12): 1365-1376.
［30］Simpson A, Petnga W, Macaulay VM, et al. Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies［J］. Target Oncol, 2017, 12(5): 571-597.
［31］Sarfstein R, Friedman Y, Attias-Geva Z, et al. Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners［J］. PLoS One, 2013, 8(4): e61537.
［32］Li L, Wang Y, Peng T, et al. Metformin restores crizotinib sensitivity in crizotinib-resistant human lung cancer cells through inhibition of IGF1-R signaling pathway［J］. Oncotarget, 2016, 7(23): 34442-34452.
［33］Hervieu A, Kermorgant S. The Role of PI3K in Met Driven Cancer: A Recap［J］. Front Mol Biosci, 2018, 5: 86.
［34］Zhao Y, Sun H, Feng M, et al. Metformin is associated with reduced cell proliferation in human endometrial cancer by inbibiting PI3K/AKT/mTOR signaling［J］. Gynecol Endocrinol, 2018, 34(5): 428-432.
［35］Zheng Z, Zhu W, Yang B, et al. The co-treatment of metformin with flavone synergistically induces apoptosis through inhibition of PI3K/AKT pathway in breast cancer cells［J］. Oncol Lett, 2018, 15(4): 5952-5958.
［36］Shi P, Liu W, Tala, et al. Metformin suppresses triple-negative breast cancer stem cells by targeting KLF5 for degradation［J］. Cell Discov, 2017, 3: 17010.
［37］Chung YC, Chang CM, Wei WC, et al. Metformin-induced caveolin-1 expression promotes T-DM1 drug efficacy in breast cancer cells［J］. Sci Rep, 2018, 8(1): 3930.
［38］Garrido MP, Vera C, Vega M, et al. Metformin prevents nerve growth factor-dependent proliferative and proangiogenic effects in epithelial ovarian cancer cells and endothelial cells［J］. Ther Adv Med Oncol, 2018, 10: 1-16.

[1]	LI Yanyang, WANG Yunjiao, LV Shichao. Effects and mechanism of traditional Chinese medicine injection in prevention and treatment of cardiotoxicity induced by antineoplastic drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 572-577.
[2]	LI Ruoning, GUO Zhanli, WANG Yuan, SUN Jianjun. Platelet-endothelial aggregation receptor 1 and its mediated signalling pathway Advances in the study of the role of platelets and endothelial cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 438-444.
[3]	WANG Siyu, LI Jiawei, LI Chenghao, LI Ling, GUO Qingyang, QIU Lu, ZHOU Shiqin, LIU Yongqi. Research progress of lactate dehydrogenase A in digestive system tumors and related drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 445-454.
[4]	LI Shan, LIU Yixin, REN Feifei, LI Xiangchen, ZHANG Zhiqing. Research progress of natural plant active ingredients in reversing tumor multidrug resistance by down-regulating P-gp [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 331-340.
[5]	WANG Dan, YAN Xiaoli, ZHANG Yuan. Helicobacter pylori infection influences the efficacy of immunotherapies for gastric cancer#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 228-234.
[6]	WANG Jie, LI Long, CHEN Feng, LIU Shengfei. Research progress of metformin in the pathogenesis of pulmonary fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 235-240.
[7]	ZHANG Wei, WANG Hongyuan, LEI Xiaohang, ZHAO Yingshuai, LV Weichao, ZHANG Jianguo. BCG + piroxicam versus BCG + gemcitabine for prevention of postoperative recurrence in intermediate- and high-risk bladder cancer and effects on serum AGR and PON1 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1146-1153.
[8]	LIU Dan, LIU Ming, JIN Liangyou, PAN Juan, XIN Haoru, LIU Mengyuan, LI Xin, ZHENG Kun, FENG Xiaoling. Research progress on the antitumor activity of costunolide [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1168-1176.
[9]	LIU Jiajun, QUE Zujun, TIAN Jianhui. Comparative study on the ability of active ingredients in Jinfukang to decrease neutrophils recruiting by lung cancer circulating tumor cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 1-9.
[10]	HUANG Hao, JIA Hong, WANG Xiaoshuang, ZHANG Lu, JIANG Hua. Effects of co-culture of dendritic cells loaded with MAGE-A3 antigen and cytokine-induced killer cells on tumor stem cells and malignant progression of endometrial cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 42-50.
[11]	GAO Lili, WANG Yuzhu, WANG Yan, LI Jian, WANG Jun. General considerations for clinical pharmacology of antitumor antibody-conjugated drugs: Implications from FDA review cases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 75-85.
[12]	LIU Jiajia, GAO Yan, ZHANG Yehui, WU Jing. Functions of CRABP2 in tumorigenesis and progression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 86-92.
[13]	HONG Ziqiang, GOU Wenxi, CUI Baiqiang, BAI Xiangdou, JIN Dacheng, GOU Yunjiu. Role of the m7G methyltransferase METTL1 in tumours [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 93-100.
[14]	WANG Xin, LIU Weiying, WU Chen, KAI Jinjun, LIANG Xuejie, CHANG Yingxuan. Metformin regulates AMPK/SREBP-1 pathway and its clinical application [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1049-1054.
[15]	WANG Yali, HUO Xulei, CHEN Feng, LI Shenglan, ZHENG Xiaohong, WANG Can, LI Wenbin. Research progress on the antitumor effect of nifurtimox [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 955-960.